Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Commercial Model: Expand Customer Base, Tighten Marketing Spend

Executive Summary

Merck expects to reduce its marketing spend by about 15 to 20 percent per product, Global Pharmaceuticals President Adam Schechter told the Pharmaceutical Strategic Alliances conference in New York on September 25

You may also be interested in...



Merck Names Ken Frazier President

The promotion moves Frazier one step closer to becoming CEO and Chairman when Dick Clark retires as expected next year.

Onsolis' REMS Is Not Template For Long-Acting Opiates - FDA

FDA signaled it is moving ahead with action on short-acting opioid products - and their Risk Evaluation and Mitigation Strategies - on a case-by-case basis with the approval of BioDelivery Sciences International's buccal fentanyl product Onsolis for cancer breakthrough pain

Onsolis' REMS Is Not Template For Long-Acting Opiates - FDA

FDA signaled it is moving ahead with action on short-acting opioid products - and their Risk Evaluation and Mitigation Strategies - on a case-by-case basis with the approval of BioDelivery Sciences International's buccal fentanyl product Onsolis for cancer breakthrough pain

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS050180

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel